DuP 105
目录号 : GC32267
DuP105是一种可口服的恶唑烷酮类化合物，能够抗葛兰素阳性菌。
Cas No.:96800-41-8
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
DuP 105 is an orally active oxazolidinone, a new class of synthetic antimicrobial agent with activity against gram-positive bacteria.
DuP 105 shows inhibitory activities against staphylococcal isolates and B. fragilis isolates with MIC90s of 4 to 16 μg/mL and 16 μg/mL[1]. DuP 105 MICs for 50% of the 216 gram-positive isolates tested (MIC50s) range from 4.0 to 16 μg/mL[2].
DuP 105 administered by either the oral or the parenteral route is protective against staphylococcal and streptococcal infections in mice with the 50% effective doses of 9 to 23 mg/kg[1].
[1]. Slee AM, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. [2]. Barry AL, et al. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988 Jan;32(1):150-2.
|
Animal experiment: |
The mice are made neutropenic by the intraperitoneal administration of 100 mg of cyclophosphamide per kg on days -5, -3, and 0 (the day of infection). The extent of immunosuppression is assessed by using a standard hematological technique to determine leukocyte counts. In all experiments, the leukocyte count in the cyclophosphamide-treated mice is less than 15% of that in nontreated mice from day 0 through day 7. On day 0, the mice are injected intraperitoneally with a bacterial inoculum suspended in 0.2 mL of saline containing 5% gastric porcine mucin. This inoculum (2×104 CFU) is fivefold that required to kill all the nontreated immunosuppressed mice in 48 h. Graded doses of the test compounds are administered by the subcutaneous or oral route at 1 and 4 h after infection. In parallel with the immunosuppressed mice, groups of nonimmunosuppressed mice are infected, and treated with the antibacterial drugs. The number of survivors on day 7 in each group is used to calculate the ED50 values of the test compounds. |
|
References: [1]. Slee AM, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. |
|
| Cas No. | 96800-41-8 | SDF | |
| Canonical SMILES | CC(NC[C@H]1CN(C2=CC=C(S(C)=O)C=C2)C(O1)=O)=O | ||
| 分子式 | C13H16N2O4S | 分子量 | 296.34 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3745 mL | 16.8725 mL | 33.745 mL |
| 5 mM | 0.6749 mL | 3.3745 mL | 6.749 mL |
| 10 mM | 0.3375 mL | 1.6873 mL | 3.3745 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet